The future facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. As a ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

Medicago’s plant-derived vaccine candidate against COVID ... co-administered with GSK’s pandemic adjuvant. Two doses of 3.75 micrograms of the vaccine are administered 21 days apart.

Lacalle Pou “welcomed GSK's announcement of the opening of one ... will concentrate the products manufactured in its different plants in Europe. Nevertheless, the agreement between GSK and ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

because with every GSK job there were several others depending on it." The new plant would have employed an additional 500 people Labour MP John Woodcock, whose Barrow in Furness constituency ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares closed today ...